CASI has announced as part of its preliminary results that it sold $4.8m worth of Evomela in Q420 and approximately $15m for the year (unaudited), exceeding the company guidance of $14m and our estimate of $14.4m. The company stated that it is targeting 50% growth in Evomela sales in 2021. Additionally, in 2021 the company will be jump starting its clinical development engine as it is expected to initiate clinical studies on a majority of its portfolio during the year.
19 Feb 2021
CASI Pharmaceuticals - Evomela sales going strong into 2021
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
CASI Pharmaceuticals - Evomela sales going strong into 2021
CASI Pharmaceuticals, Inc. (CASI:NAS) | 0 0 0.0%
- Published:
19 Feb 2021 -
Author:
Dr Nathaniel Calloway -
Pages:
6
CASI has announced as part of its preliminary results that it sold $4.8m worth of Evomela in Q420 and approximately $15m for the year (unaudited), exceeding the company guidance of $14m and our estimate of $14.4m. The company stated that it is targeting 50% growth in Evomela sales in 2021. Additionally, in 2021 the company will be jump starting its clinical development engine as it is expected to initiate clinical studies on a majority of its portfolio during the year.